期刊文献+

t—PSA与c—PSA对前列腺癌和良性前列腺增生的鉴别诊断意义 被引量:4

The using Value of t-PSA and c-PSA to differential diagnosis the prostate neoplasms and BPH
下载PDF
导出
摘要 目的研究复合前列腺特异性抗原(c—PSA)、总前列腺特异性抗原(t—PSA)在鉴别诊断前列腺癌和良性前列腺增生时的应用价值。方法选择两组实验对象,PCa组89例经B超、病理确诊的前列腺癌(PCa)者。BPH组为111例良性前列腺增生患者。采用化学发光法检测其c—PSA、t-PSA,记录结果并进干亍统计分析。结果PCa和BPH组的c—PSA、t—PSA和年龄值,BPH和PCa组t-PSA含量(3.6±2.4)ng/ml、(15.2±16.2)ng/ml,差异有极显著性(P〈0.01),年龄值两组间,差异兀显著性(P〉0.05)。t-PSA的cutoff为10ng/ml时,Pca89例中45例为假阴性(50.6%),t—PSA的cutoff为2.5ng/ml时,Pca89例中24例为假阴性(27.0%),但假阳性率相应升高。BPH和Pca的c—PSA含量(0.08±0.06)ng/ml、(28.9±37.6)ng/ml(P〈0.01),c—PSA的cutoff为2.5ng/ml时,Pca89例中18例为假阴性(20.2%1。t—PSA的cutoff为10ng/ml时,与c—PSA同时阳性占46.1%,而将t—PSA的cutoff定为2.5ng/ml时,与c—PSA同时阳性占69.7%。结论c—PSA在t-PSA〈10ng/mL的特异性优于t—PSA,t-PSA的cutoff为10ng/ml的设置过高,建议将其调整为2.5ng/ml,结合c—PSA(cutoff:2.5ng/ml)将有效提高PCa诊断的特异性和灵敏度。 Objective To research the using value of t-PSA and e-PSA to differential diagnosis the prostate neoplasms and BPH. Methods The level of t-PSA and e-PSA were measured in the 89 eases of PCa,111 cases of BPH by Chemiluminescence analysis. Results The level of t-PSA was (3.6 ± 2.4) ng/ml(BPH) and (15.2 ±16.2) ng/ml(PCa) (P〈0.01). The false negative was 50.6% (cutoff= 10ng/ml) and 27.0% (cutoff =2.5ng/ml). The level of c-PSA was (0.08 ± 0.06) ng/ml(BPH) and (28.9 ±37.6) ng/ml(PCa) (P〈0.01), The false negative was 20.2% (cutoff =2.5ng/ml). When the cutoff of t-PSA was 2.5 ng/ml, to combine the c-PSA would raise the positive up to 69.7 %. Conclusion When the cutoff of t-PSA was 10. 0 ng/ml, the c-PSA was significantly higher than t-PSA .We suggest adjust the cutoff of t-PSA to 2.5 ng/ml, and to combine the c-PSA would significant raise the Sensitivity and Specificity by diagnosis the prostate neoplasms.
出处 《国际医药卫生导报》 2010年第5期574-576,共3页 International Medicine and Health Guidance News
关键词 总前列腺特异性抗原(t-PSA) 复合前列腺特异性抗原(c-PSA) 前列腺癌(PCa) 前列腺增生(BPH) Total prostate-specific antigen(t-PSA) Complexed prostate-specific antigen(c-PSA) Prostatic neoplasms(PCa) Benign prostatic hypei'plasia(BPH)
  • 相关文献

参考文献6

二级参考文献14

  • 1Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med, 1991, 324:1156-1161.
  • 2Harada M, Nemoto R, Uchida K, et al. Histopathological comparison of prostatic adenocarcinoma in Janpan and the United States. J Japanese Urolology, 1993, 84: 1110-1118.
  • 3Humphrey PA, Keetch DW, Smith DS, et al. Prospective characterization of pathological feature of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol, 1996, 155: 816-820.
  • 4Bostick DG, Dundore PA, eds. Biopsy pathology of the prostate. New York: Chapman & Hall Medical, 1997.141-163.
  • 5Rigley JR, Bullock M, and Amin M. Small glandular patterns in the prostate: Differential diagnosis of small acinar carcinoma. In: Foster CS and Bostwick DG, eds. Pathology of prostate. Philadelphia: Sauders Company, 1998.126-155.
  • 6Shirley SE, Escoffery CT, Sargeant LA, et al. Clinicopathological features of prostate cancer in Jamaican men. BJU Int, 2002, 89: 390-395.
  • 7Shizuka O, Satoh T, Kobayashi S, et al. Mass screening for prostate cancer in Nagano. Hinyokika Kiyo, 2001, 47: 769-772.
  • 8Catalona WJ, Richie JP, Ahmann FR. et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol, 1994, 151: 1283-1290.
  • 9陈炜,梅骅,郑克立,李晓飞.超声引导的经直肠前列腺穿刺活检术(附121例报告)[J].中华泌尿外科杂志,1997,18(6):359-361. 被引量:29
  • 10杨立.游离PSA对前列腺癌检测的新进展[J].国外医学(泌尿系统分册),1998,18(2):52-54. 被引量:18

共引文献39

同被引文献50

  • 1艾金霞 ,于秀艳 ,王雪松 .血清hK2 ELISA方法的建立及在前列腺癌诊断中的应用[J].北华大学学报(自然科学版),2005,6(2):125-128. 被引量:4
  • 2丁国芳,李继承,徐银峰,孙瑜,陶莉.中国人前列腺癌VEGF-C mRNA、VEGFR-3和CD31表达与肿瘤转移的关系[J].实验生物学报,2005,38(3):257-264. 被引量:7
  • 3顾平,盛世乐,黄钢.PSA及其它肿瘤标志物在前列腺癌中的应用[J].放射免疫学杂志,2006,19(6):507-512. 被引量:6
  • 4TANGUARY S,BEJIN L R,ELHILALI M M,et al.Comparative evaluation of total PSA,free/total PSA,and complexed PSA in prostate cancer detection[J].Urology,2002,59(2):261-265.
  • 5Kohli M, Tindall DJ. New developments in the medical management of prostate cancer[J]. Mayo Clin Proc ,2010,85 ( 1 ) :77-86.
  • 6Roddan AW,Duffy MJ, Hamdy FC,et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10ng/ml: systematic review and meta-analysis[ J]. Eur Uro1,2005,48 ( 3 ) : 386-399.
  • 7Thompson M, Lapointe J, Choi YL, et al. Identification of candidate prostate cancer genes through comparative expression-profiling of seminal vesicle [ J ]. Prostate,2008,68 ( 11 ) : 1248-1256.
  • 8Jennbacken K,Vallbo C, Wang W , et al. Expression of vascular endothelial growth factor ( VEGF-C ) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis[J]. The Prostate,2005,65 (2) : 110-116.
  • 9Sung MT, Jiang Z, Montioni R,et al. Alpha-methylacyl-CoA racemase (P504s)/34 beta E12/p63 triple cocktail stain in prostate ade- nocarcinoma after hormonal therapy [ J ]. Hum Pathol, 2007,38 ( 2 ) : 332-341.
  • 10Luo J, Zha S, Goge WR, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer [ J ]. Cancer Res, 2002,62 ( 8 ) :2200-2226.

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部